Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG's Board Proposes Martin Nicklasson To Succeed Chairman Werner Henrich
Basilea Pharmaceutica AG announced that its Board of Directors proposes Dr. Martin Nicklasson as designated non-executive Chairman of the Board of Directors to succeed Werner Henrich whose term will end at the upcoming AGM. Mr. Henrich will not stand for re-election as he will reach the statutory age limit for board members in 2013. Dr. Martin Nicklasson proposed for election to the Basilea Board of Directors.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG reports granting of U.S. orphan drug designation to isavuconazole for treatment of invasive candidiasis
- Basilea Pharmaceutica AG receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis
- Basilea Pharmaceutica AG confirms FY 2014 guidance
- Basilea Pharmaceutica AG submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
Latest Key Developments in Biotechnology
- Ablynx NV on track to start Phase III study in patients with acquired TTP in mid 2015
- LBT Innovations Limited completes Australian clinical trials of APAS technology
- Amarantus announces positive preclinical data on the effects of MANF on Vision in model of retinitis pigmentosa
- Medgenics Inc prices public offering of common stock
- Share this
- Digg this